Bristol Myers Squibb (CELG-RI) EBITDA Margin (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly EBITDA Margin of 2.77% for Q2 2026, up 1581.0% year-over-year from 0.17% in Q2 2025, and up 275.18% quarter-over-quarter from 1.58% in Q1 2026.
Bristol Myers Squibb (CELG-RI) EBITDA Margin (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported EBITDA Margin for 18 consecutive years, with 2.77% the latest figure, recorded in Q2 2026.
- In Q2 2026, EBITDA Margin rose 1581.0% year-over-year to 2.77%; the TTM figure through Jun 2026 stood at 5.63% (up 1026.0% YoY), while the FY2025 annual figure was 9.56%, up 3671.0% from the prior year.
- EBITDA Margin climbed to 2.77% in Q2 2026 per CELG-RI's latest filing, from 1.58% in the prior quarter.
- Across five years, EBITDA Margin topped out at 2.77% in Q2 2026 and bottomed at 121.77% in Q1 2024.
- Historically, EBITDA Margin has averaged 14.62% across 5 years, with a median of 6.58% in 2022.
- Annual changes were most pronounced in 2024 — EBITDA Margin slumped 12357 bps — and 2025, when it surged 12122 bps.
- Bristol Myers Squibb's EBITDA Margin stood at 6.44% in 2022, then sank by 45 bps to 9.33% in 2023, then slumped by 303 bps to 37.57% in 2024, then soared by 44 bps to 21.01% in 2025, then surged by 113 bps to 2.77% in 2026.
- Business Quant data shows CELG-RI's EBITDA Margin at 2.77% in Q2 2026, 1.58% in Q1 2026, and 21.01% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.66 Bn | 632.90 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 470.02 Bn | 463.46 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 379.06 Bn | 371.92 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 302.95 Bn | 295.26 Bn | 11.24 Bn | 32.97% |
| 5 | Astrazeneca | 257.68 Bn | 252.78 Bn | 12.86 Bn | 20.57% |
| 6 | Amgen | 236.97 Bn | 222.98 Bn | 7.24 Bn | 34.95% |
| 7 | Gilead Sciences | 182.78 Bn | 179.60 Bn | 6.22 Bn | -133.21% |
| 8 | Pfizer | 161.51 Bn | 149.81 Bn | 10.94 Bn | 28.37% |
| 9 | Gsk | 105.54 Bn | 101.37 Bn | 8.24 Bn | 5.72% |
| 10 | Bristol Myers Squibb | 208.28 Mn | -10.86 Bn | 9.25 Bn | 2.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.77% |
| Mar 31, 2026 | -1.58% |
| Dec 31, 2025 | -21.01% |
| Sep 30, 2025 | -2.63% |
| Jun 30, 2025 | -13.03% |
| Mar 31, 2025 | -0.55% |
| Dec 31, 2024 | -37.57% |
| Sep 30, 2024 | -10.77% |
| Jun 30, 2024 | -16.24% |
| Mar 31, 2024 | -121.77% |
| Dec 31, 2023 | -9.33% |
| Sep 30, 2023 | -3.36% |
| Jun 30, 2023 | -9.06% |
| Mar 31, 2023 | 1.80% |
| Dec 31, 2022 | -6.44% |
| Sep 30, 2022 | -1.28% |
| Jun 30, 2022 | -6.41% |
| Mar 31, 2022 | -6.73% |
| Dec 31, 2021 | -4.16% |
| Sep 30, 2021 | -1.15% |